Inovio Pharmaceuticals Inc (NASDAQ: INO). Extremely significant negative changes in investment behavior have recently occurred: negative upside/downside volume developed, and the stock fell on very heavy volume.
Inovio Pharmaceuticals Inc (NASDAQ: INO). Important negative changes in fundamentals have recently occurred: the stock’s power rating fell below 50, and significant quarterly sales deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
INO’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Inovio Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Inovio Pharmaceuticals has a slightly negative Power Rating of 34 and a poor Appreciation Score of 16, triggering the Lowest Value Trend Rating.
Recent Price Action
Inovio Pharmaceuticals Inc (NASDAQ: INO) stock suffered a large decline of -9.3% on 9/23/24. The stock closed at $5.88. Moreover, this decline was accompanied by exceptionally high trading volume at 202% of normal. The stock has performed in line with the market over the last nine months and has declined -13.7% during the last week.
Be the first to comment